When was Artiva founded?

Artiva was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Artiva located?

Artiva is headquartered in San Diego, United States. It is registered at Rīga, Sila iela 9.

How many employees does Artiva have?

As of May 31, 2026, the latest employee count at Artiva is 105.

Is Artiva a funded company?

Artiva is a funded company, having raised a total of $198M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 2019.

When was the latest funding round of Artiva?

Artiva's latest funding was a $***** Series B round on Feb 22, 2021, with participation from 15 investors.

What is the annual revenue of Artiva?

Annual revenue of Artiva is less than $1M as on Dec 31, 2024

Where does Artiva rank among its competitors?

Artiva ranks 516th amongst 3236 active competitors, of which 1113 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Artiva?

Artiva's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Artiva - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for autoimmune diseases and cancer. The product pipeline includes AB-101 is an ADCC enhancer for B-cell malignancies, AB-201 and AB202 are targeted CAR-NK are allogeneic NK cell therapies that work on innate biology and enhance the efficacy through antibody combination therapy and genetic engineering.

Website: artivabio.com
Social
Email ID: *****@artivabio.com
Phone Number: +1 **********
Registered Address: Rīga, Sila iela 9

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Public

Total Funding

$198M in 3 rounds

Latest Funding Round

Series B, Feb 22, 2021, $*****

Investors

Venrock & 16 more

Ranked

516^th among 3236 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

105 as on May 31, 2026

Similar Companies

Senti Bio & 140 more

Exit Details

Public

View Artiva's full profile

Artiva is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ARTIVA BIOTHERAPEUTICS, INC. CIN: 32069811928 , United States, Active	Feb 20, 2019	$0 - $1M (As on Dec 31, 2024)	-	-
Artiva Biotherapeutics, Inc CIN: 833614316 , United States, Active	Feb 19, 2019	-	86 (As on Dec 31, 2024)	-
ARTIVA CIN: 40003530849 , Latvia, Active	Feb 07, 2001	€0 - €1M (As on Dec 31, 2024)	5 (As on Dec 31, 2022)	-

Artiva got listed on Jul 19, 2024.

Click here to take a look at Artiva's IPO in detail

Artiva has raised a total funding of $198M over 3 rounds. Its first funding round was on Feb 2019. Its latest funding round was a Series B round on Feb 22, 2021 for $*****. 15 investors participated in its latest round. Artiva has 17 institutional investors.

Here is the list of recent funding rounds of Artiva:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2021	8691343	Series B	3923294	2693872	4767576	2112810
Jun 26, 2020	5448925	Series A	4143631	3162339	7694439	Medivate Partners & 1 more
Feb 2019	1312447	Seed	3916888	8260040	4947223	GC Green Cross Lab Cell

Access funding benchmarks and valuations. Sign up today!

View details of Artiva's funding rounds and investors

Artiva's employee count trend

Artiva has 105 employees as of May 26. Here is Artiva's employee count trend over the years:

Uncover Artiva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Artiva include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Artiva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Google Ventures & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Delos Capital Partners ... & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Avidity Partners, Foresite Capital & 16 others	71/100
516th	Artiva 2018, San Diego (United States), Public	Developer of therapeutics for autoimmune diseases and cancer	$198M	Wellington, RA Capital Management & 15 others	53/100